Table 1

Demographic and clinical characteristics of patients with clinically early-stage high-grade neuroendocrine cervical carcinoma*

CharacteristicOverall cohort (n=100)Parametrial involvement (n=10)No parametrial involvement (n=90)P value
Age, median (range), years35.0 (22.0–65.0)41.5 (30.0–63.0)35.0 (22.0–65.0)0.06
BMI, median (range), kg/m2 25.1 (14.4–60.5)25.3 (16.7–32.8)25.1 (14.4–60.5)0.43
Current or former smoker0.48
 Yes43 (43)6 (60)37 (41)
 No56 (56)4 (40)52 (58)
 Not reported1 (1)0 (0)1 (1)
FIGO (2018) stage
 IA1, IA211 (11)0 (0)11 (12)
 IB143 (43)0 (0)43 (48)
 IB223 (23)0 (0)23 (26)
 IIA11 (1)0 (0)1 (1)
 IIB2 (2)2 (20)0 (0)
 IIIC1p20 (20)8 (80)12 (13)
Histology†0.46
 Pure HGNECC51 (51)4 (40)47 (52)
 Mixed (HGNECC+other histology)49 (49)6 (60)43 (48)
Pre-treatment tumor size0.05
 ≤2 cm48 (48)2 (20)46 (51)
 >2 cm47 (47)8 (80)39 (43)
 Not reported5 (5)0 (0)5 (6)
Tumor size in surgical specimen0.06
 No residual disease19 (19)0 (0)19 (21)
 ≤2 cm27 (27)2 (20)25 (28)
 >2 cm and ≤4 cm41 (41)7 (70)34 (38)
 >4 cm2 (2)1 (10)1 (1)
 Not reported11 (11)0 (0)11 (12)
Positive nodes20/94 (21)8/10 (80)12/84 (14)<0.0001
Number of positive nodes, median (range)2.0 (1.0–6.0)2.0 (1.0–4.0)2.0 (1.0–6.0)0.49
Depth of invasion0.13
 ≤10 mm49/72 (68)4/9 (44)45/63 (71)
 >10 mm23/72 (32)5/9 (56)18/63 (29)
Lymphovascular space invasion0.11
 No19/24 (19)0/10 (0)19/69 (28)
 Yes60/79 (76)10/100 (100)50/69 (72)
Positive vaginal margin3 (3)2 (20)1 (1)0.03
Ovarian compromise‡1/57 (2)0/6 (0)1/51 (2)1
  • *Results reported as number of patients (%) except when otherwise specified.

  • †Final histology: combination of pre-treatment histology and final specimen pathology.

  • ‡Only reported for patients with bilateral salpingo-oophorectomy or unilateral oophorectomy.

  • BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics ; HGNECC, high-grade neuroendocrine cervical carcinoma .